162 related articles for article (PubMed ID: 3282911)
1. The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia.
Stafanger G; Garne S; Howitz P; Morkassel E; Koch C
Eur Respir J; 1988 Feb; 1(2):161-7. PubMed ID: 3282911
[TBL] [Abstract][Full Text] [Related]
2. N-acetylcysteine in cystic fibrosis and Pseudomonas aeruginosa infection: clinical score, spirometry and ciliary motility.
Stafanger G; Koch C
Eur Respir J; 1989 Mar; 2(3):234-7. PubMed ID: 2659383
[TBL] [Abstract][Full Text] [Related]
3. Ciliary disorientation alone as a cause of primary ciliary dyskinesia syndrome.
Rayner CF; Rutman A; Dewar A; Greenstone MA; Cole PJ; Wilson R
Am J Respir Crit Care Med; 1996 Mar; 153(3):1123-9. PubMed ID: 8630555
[TBL] [Abstract][Full Text] [Related]
4. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.
Quan JM; Tiddens HA; Sy JP; McKenzie SG; Montgomery MD; Robinson PJ; Wohl ME; Konstan MW;
J Pediatr; 2001 Dec; 139(6):813-20. PubMed ID: 11743506
[TBL] [Abstract][Full Text] [Related]
5. Lung function in patients with primary ciliary dyskinesia: an iPCD Cohort study.
Halbeisen FS; Goutaki M; Spycher BD; Amirav I; Behan L; Boon M; Hogg C; Casaulta C; Crowley S; Haarman EG; Karadag B; Koerner-Rettberg C; Loebinger MR; Mazurek H; Morgan L; Nielsen KG; Omran H; Santamaria F; Schwerk N; Thouvenin G; Yiallouros P; Lucas JS; Latzin P; Kuehni CE
Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 30049738
[TBL] [Abstract][Full Text] [Related]
6. Expiratory ventilatory capacity measurements in children with cystic fibrosis treated by oral acetylcysteine.
Steil E; Niessen KH
Eur J Respir Dis Suppl; 1980; 111():132-3. PubMed ID: 6938398
[No Abstract] [Full Text] [Related]
7. Effects of montelukast treatment on clinical and inflammatory variables in patients with cystic fibrosis.
Stelmach I; Korzeniewska A; Stelmach W; Majak P; Grzelewski T; Jerzynska J
Ann Allergy Asthma Immunol; 2005 Oct; 95(4):372-80. PubMed ID: 16279568
[TBL] [Abstract][Full Text] [Related]
8. Fitness and lung function in children with primary ciliary dyskinesia and cystic fibrosis.
Ring AM; Buchvald FF; Holgersen MG; Green K; Nielsen KG
Respir Med; 2018 Jun; 139():79-85. PubMed ID: 29858006
[TBL] [Abstract][Full Text] [Related]
9. Secondary ciliary dyskinesia in upper respiratory tract.
Bertrand B; Collet S; Eloy P; Rombaux P
Acta Otorhinolaryngol Belg; 2000; 54(3):309-16. PubMed ID: 11082767
[TBL] [Abstract][Full Text] [Related]
10. A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis.
Schnabel D; Grasemann C; Staab D; Wollmann H; Ratjen F;
Pediatrics; 2007 Jun; 119(6):e1230-8. PubMed ID: 17545356
[TBL] [Abstract][Full Text] [Related]
11. Do pulmonary and extrapulmonary features differ among cystic fibrosis, primary ciliary dyskinesia, and healthy children?
Denizoglu Kulli H; Gurses HN; Zeren M; Ucgun H; Cakir E
Pediatr Pulmonol; 2020 Nov; 55(11):3067-3073. PubMed ID: 32877003
[TBL] [Abstract][Full Text] [Related]
12. Function and ultrastructure of cilia in primary ciliary dyskinesia.
Felix H; Holzmann D
Schweiz Med Wochenschr; 2000 May; 130(19):699-704. PubMed ID: 10846764
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial.
Conrad C; Lymp J; Thompson V; Dunn C; Davies Z; Chatfield B; Nichols D; Clancy J; Vender R; Egan ME; Quittell L; Michelson P; Antony V; Spahr J; Rubenstein RC; Moss RB; Herzenberg LA; Goss CH; Tirouvanziam R
J Cyst Fibros; 2015 Mar; 14(2):219-27. PubMed ID: 25228446
[TBL] [Abstract][Full Text] [Related]
14. Ventilation inhomogeneity in children with primary ciliary dyskinesia.
Green K; Buchvald FF; Marthin JK; Hanel B; Gustafsson PM; Nielsen KG
Thorax; 2012 Jan; 67(1):49-53. PubMed ID: 21953064
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment.
Shah PI; Bush A; Canny GJ; Colin AA; Fuchs HJ; Geddes DM; Johnson CA; Light MC; Scott SF; Tullis DE
Eur Respir J; 1995 Jun; 8(6):954-8. PubMed ID: 7589382
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.
Deterding R; Retsch-Bogart G; Milgram L; Gibson R; Daines C; Zeitlin PL; Milla C; Marshall B; Lavange L; Engels J; Mathews D; Gorden J; Schaberg A; Williams J; Ramsey B;
Pediatr Pulmonol; 2005 Apr; 39(4):339-48. PubMed ID: 15704203
[TBL] [Abstract][Full Text] [Related]
17. Oral acetylcysteine in cystic fibrosis. A co-operative study.
Götz M; Kraemer R; Kerrebijn KF; Popow C
Eur J Respir Dis Suppl; 1980; 111():122-6. PubMed ID: 7011832
[No Abstract] [Full Text] [Related]
18. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function.
Accurso FJ; Moss RB; Wilmott RW; Anbar RD; Schaberg AE; Durham TA; Ramsey BW;
Am J Respir Crit Care Med; 2011 Mar; 183(5):627-34. PubMed ID: 21169471
[TBL] [Abstract][Full Text] [Related]
19. Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial.
Robinson P; Schechter MS; Sly PD; Winfield K; Smith J; Brennan S; Shinkai M; Henke MO; Rubin BK
Pediatr Pulmonol; 2012 Jun; 47(6):551-7. PubMed ID: 22266895
[TBL] [Abstract][Full Text] [Related]
20. Effect of high-dose ibuprofen in patients with cystic fibrosis.
Konstan MW; Byard PJ; Hoppel CL; Davis PB
N Engl J Med; 1995 Mar; 332(13):848-54. PubMed ID: 7503838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
